● Recruiting

Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis

Condition: Myasthenia Gravis · Sponsor: UCB Biopharma SRL

PhasePhase 4

Planned participants40

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

The purpose of the study is to assess the clinical efficacy of rozanolixizumab in adult Chinese participants with generalized myasthenia gravis (gMG) in the first Treatment Cycle.

This description comes directly from the study's public registry record.

Talk to the study team

UCB Cares · +18445992273 · ucbcares@ucb.com

Always discuss trial participation with your own doctor first.

Locations (12)

Mg0033 20040	Beijing, China	Recruiting
Mg0033 20261	Changchun, China	Recruiting
Mg0033 20295	Changsha, China	Recruiting
Mg0033 20348	Fuzhou, China	Recruiting
Mg0033 20269	Guangzhou, China	Recruiting
Mg0033 20185	Jinan, China	Recruiting
Mg0033 20347	Jinan, China	Recruiting
Mg0033 20172	Shanghai, China	Recruiting
Mg0033 20184	Shenzhen, China	Recruiting
Mg0033 20204	Suzhou, China	Recruiting
Mg0033 20180	Wuhan, China	Recruiting
Mg0033 20349	Xuzhou SHI, China	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07246564